Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

Current management of HCV infection is based on Direct-Acting Antiviral Drugs (DAAs).
However, resistance-associated mutations, especially in the NS3 and NS5B regions are …

Background Cytomegalovirus (CMV) is a viral infection which establishes lifelong latency,
often reactivating and causing disease in immunosuppressed individuals, including …

Aim This study aimed to investigate the role of resistance‐associated substitutions (RASs) to
direct‐acting‐antivirals (DAAs) in HCV genotype 3 (GT3). Methods Within the Italian …

ABSTRACT Background Hepatitis C virus (HCV) is a global public health problem. Second-
generation direct-acting antivirals targeting non-structural regions on the viral genome are …

Hepatitis C virus (HCV) is associated with liver damage and an increased progression rate
to cirrhosis and hepatocellular carcinoma. In Portugal, it is prevalent in vulnerable …

Abstract Background Hepatitis C virus (HCV) infection can now be cured with well-tolerated
direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the …

The availability of all oral direct acting antiviral agents (DAAs) has revolutionized the
management of HCV infections in recent years, allowing to achieve a sustained virological …

Resistance-associated substitutions (RASs) may exist prior to treatment and contribute to the
failure of treatment with direct-acting antivirals (DAAs). As the major site of HCV replication …

O vírus da Hepatite C (VHC) é responsável pela Hepatite C, uma doença que pode conduzir
a danos hepáticos consideráveis, nomeadamente cirrose e carcinoma hepatocelular. Em …